

**Acute Leukemia**

**26.11.2020**

Abdallah Al-Abbadi.MD.FRCP.FRCPath

Feras Fararjeh MD

## Case 9: Acute Leukemia

29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising and hemorrhagic spots on her trunk and limbs.

Physical findings

Spleen ++. Gum &

Skin shown.

Fever 40

BP 100/70 P 102



Hb 9, WBC 54K

Blasts 80%, Plt 24K


PT 18/13, PTT 40/32,

Urine: RBC +3, WBC +++, Bacteria

+++. Bld culture + E.Coli.




# Why is AML a disease of getting old?



Source: SEER data 2005-2009.

## AML: Epidemiology Incidence of AML Increases with Age




Ag

Available at <http://seer.cancer.gov/statfacts/html/amyl.ht>  
<http://seer.cancer.gov/statfacts/html/aly1.html>. Accessed


## AML: Epidemiology Survival Decreases with Age

Age-Associated 5-Year Relative Survival, 1996 - 2003



<http://seer.cancer.gov>. Accessed October 19, 2007.

# Incidence of clonal hematopoiesis increases with age



## Summary

### **Why do we develop AML as we get older?**

Hematopoietic stem cells acquire mutations over their lifetime.

Most are benign (passenger).

Occasionally one leads to clonal hematopoiesis.

Each division within this clone results in further mutations, and facilitate subclonal evolution and progression to MPD/MDS/AML.

## AML: Definition

- **De novo AML**
- **Secondary AML**
  - Clinical history of:
    - Myelodysplastic syndrome
    - Myeloproliferative disorder
    - Prior exposure to radiation, select chemicals, or chemotherapy

## AML: Classification French-American British (FAB)

|           |  |
|-----------|--|
| <b>M0</b> | <b>Undifferentiated</b>                |
| <b>M1</b> | <b>Myeloblastic without maturation</b> |
| <b>M2</b> | <b>Myeloblastic with maturation</b>    |
| <b>M3</b> | <b>Promyelocytic</b>                   |
| <b>M4</b> | <b>Myelomonocytic</b>                  |
| <b>M5</b> | <b>Monocytic</b>                       |
| <b>M6</b> | <b>Erythroid</b>                       |
| <b>M7</b> | <b>Megakaryoblastic*</b>               |

\*Added in 1985

Bennett JM et al. *Br J Haematol*. 1976;33:451-458.; Bennett JM et al. *Ann Intern Med*. 1985;103:460-46

## AML: Classification World Health Organization (WHO)

- **AML with recurrent genetic abnormalities**
  - t(8;21)(q22;q22)
  - inv(16)(p13q22) or t(16;16)(p13;q22)
  - t(15;17)(q22;q12)
  - 11q23 abnormalities
- **AML with multilineage dysplasia**
- **AML and myelodysplastic syndromes (MDS); therapy related**
- **AML not otherwise categorized**



# AML: Prognostic Factors

- Age
- Cytogenetics
- Molecular mutation
- Secondary AML
- Performance status
- Leukocyte count at presentation

# AML: Prognostic Factors


## Frequency of Cytogenetic Risk Groups

|              | Karyotype             | Frequency (%) |
|--------------|-----------------------|---------------|
| Favorable    | t(8;21)               | 5 - 10        |
|              | inv16                 | 5 - 10        |
|              | t(15;17)              | 5 - 10        |
| Intermediate | Diploid,-Y            | 40 - 50       |
| Unfavorable  | -5 / -7               | 20 - 30       |
|              | +8                    | 10            |
|              | 11q23, 20q-,<br>other | 10 - 20       |

## AML: Karyotype and Prognosis

Results from Cancer and Leukemia Group B (CALGB 8641)

Overall Survival Patients age 15 - 86 with untreated AML



Byrd JC et al. *Blood*. 2002;100:4325-4336.

Jabbour EJ et al. *Mayo Clin Proc*. 2006;81(2):247-260.

# AML: Treatment Overview

## Remission Induction

- **Goal to reduce tumor burden & restore normal hematopoiesis**
- **“7 + 3”: Continuous infusion cytarabine x 7 days and an anthracycline x 3 days remains standard of care**
  - ? Best anthracycline
  - ? Intensification with high dose cytarabine (HDAC) or etoposide
  - ? Timed sequential chemotherapy

# AML: Treatment Overview

## Post-Remission (Consolidation) Therapy

- Once in CR, long-term survival requires post-remission treatment
  - Chemotherapy **versus**
  - Allogeneic stem cell transplant **versus**
  - Autologous stem cell transplant

# **New approach in treating AML**

1- Risk stratification


2- Incorporation of Monoclonal antibodies

3- Incorporation of small molecules and targeted therapy



# Promyelocytic leukemia M3

1. Associated with t (15;17) involving the retinoic acid receptor (RAR) gene .
  2. Good prognosis category.
  3. Commonly associated with **DIC**.
- Prominent Auer rods.

# Auer rods in AML



# t(15;17) translocation in AML





# M4: Myelomonocytic leukemia

- With inverted 16 and associated eosinophilia  
this is a good prognostic category
- Associated with leukemia cutis.
- CNS disease may occur.

# Treatment aml/m3

- **Tretinoin (all tran retinoic acid)** is an oral drug that induces the differentiation of leukemic cells bearing the t(15;17); it is not effective in other forms of AML.
- APL is responsive to **cytarabine** and **daunorubicin**, but about 10% of patients treated with these drugs die from DIC induced by the release of granule components by dying tumor cells.

# ATRA Syndrome

- Tretinoin does not produce DIC but produces another complication called the ***retinoic acid syndrome***.
- Occurring within the first 3 weeks of treatment, it is characterized by **fever, dyspnea, chest pain, pulmonary infiltrates, pleural and pericardial effusions, and hypoxia**.
- The syndrome is related to adhesion of differentiated neoplastic cells to the pulmonary vasculature endothelium.
- Glucocorticoids, chemotherapy, and/or supportive measures can be effective.
- **The mortality of this syndrome is about 10%.**

## Case 9 B

A 19 yr old male has been complaining of fatigue, joint pain for 2 wks. He was admitted because he had a high fever. P/E he looked ill and pale, with Temp 40, BP 100/70, p 104, he had generalized LN enlargement, badly infected tonsil. His spleen was enlarged. Hb 9.5g/dl, plts 45k, WBC 90k: blasts 88%, other cells 12%. LDH 1600, Uric acid 13, Ca 7, PO4 5, Creat 3, K, 6.1, PT, PTT, TT, Nml.



### Flow

CD19(+), Tdt(+),

CD10(+), Cylg(-),

Karyotyping normal

PAS +++



# Common manifestations of acute leukemia

## **1-Manifestations of BM replacement**

Anemia

Thrombocytopenia

Neutropenia

## **2-Infiltration of extra BM tissues:**

LN, Gums, skin, CNS, others

## **3-Release of granules/ metabolites:**

DIC/ gout, ARF

## **4-Hyperviscosity**

# Biology of Adult Acute Lymphoblastic Leukemia

## Classification:

- Morphologic Features
- Immunophenotyping

# Morphologic subtypes of acute lymphoblastic leukemias (FAB classification)

| <u>Subtype</u> | <u>Morphology</u>  | <u>Occurrence (%)</u> |
|----------------|--|-----------------------|
| L1             | Small round blasts clumped chromatin                         | 75                    |
| L2             | Pleomorphic larger blasts<br>clefated nuclei, fine chromatin | 20                    |
| L3             | Large blasts, nucleoli, vacuolated cytoplasm                 | 5                     |


# Antigen independent phase

Bone marrow

Blood

# Antigen dependent phase

Secondary lymphoid organs





# Immunologic classification of acute lymphoblastic leukemias

## B-lineage (80%)

### Markers

|          |  |
|----------|--|
| Pro-B    | CD19(+), Tdt(+), CD10(-), Cylg(-),         |
| Common   | CD19(+), Tdt(+), CD10(+), Cylg(-),         |
| Pre-B    | CD19(+), Tdt(+), CD10(+), Cylg(+), Smlg(-) |
| Mature-B | CD19(+), Tdt(+), CD10(±), Cylg(±), Smlg(+) |

## T-lineage (20%)

|          |                         |
|----------|-------------------------|
| Pre-T    | CD7(+), CD2(-), Tdt(+), |
| Mature-T | CD7(+), CD2(+), Tdt(+), |

# Chromosomal/molecular abnormalities with prognostic significance in ALL

## Better prognosis

- normal karyotype
- hyperdiploidy

## Poor prognosis

- t (8; 14)
- t (4; 11)

## Very poor prognosis

- t (9; 22); BCR/ABL (+)

# **Risk classification in ALL**

- 1. Standard risk**
- 2. High risk**
- 3. Very high risk**

# High-risk ALL/ very high risk

1. Pre - T
2. Pro - B
3. Age > 35 years,
4. WBC > 30 G/L in B-ALL  
> 100 G/L in T-ALL
5. No remission after 4 weeks of induction therapy
6. Chromosome Philadelphia - positive or BCR/ABL (+)

# **In ALL the choice of treatment-strategy depends on:**

1. Risk Stratification
2. Immunophenotype of leukemic cells
  - T lineage,
  - early B lineage,
  - mature B lineage,
3. Age and biological condition
4. Goal of treatment

# Treatment Approach in ALL

## CNS Prophylaxis

Intrathecal methotrexate, Ara-C, Steroids, Craniospinal irradiation

### INDUCTION

1 month

Anthracycline  
Vincristine  
Cyclophosphamide  
L-asparaginase  
Methotrexate  
Ara-C  
Steroids

**GOAL:** rapidly restore normal

### CONSOLIDATION / INTENSIFICATION

4-8 months

Chemotherapy  
Allogeneic Stem Cell Transplant

**GOAL:** prevent emergence of resistant clones  
eliminate residual disease

### MAINTENANCE

2-3 years

6-MP  
Methotrexate  
Vincristine  
Steroids

**GOAL:** eliminate residual disease

# **Allogeneic BMT for ALL**

**High risk ALL**

**Unacceptable minimal residual disease**

**Availability of a donor**

**Good performance status**

**Aim to cure**